Life Sciences Investment Forum 2026

Leads regulatory and transactional matters that shape the health and life sciences landscape

Represents private capital investors across buy-side and sell-side dealmaking in the sector

Helps clients structure innovative strategies with business-focused guidance across borders, and across health and life sciences subsectors

Mergers, stock and asset deals, and leveraged buyouts

Venture capital investments and growth financings

Joint ventures, restructurings, and recapitalizations

Private equity and venture-backed transactions

Andrew J. Warmus focuses his practice on domestic and cross-border mergers and acquisitions, joint ventures, and other strategic transactional matters. He has broad experience representing private equity firms and other financial sponsors, multinational public companies, private companies, and founders in material and transformative transactions across multiple industries, with significant experience in the life sciences sector, including pharmaceuticals, diagnostics, and medical devices.

Andrew advises buyers and sellers in acquisitions, divestitures, and strategic transactions often involving complex, multijurisdictional carve-out transactions in regulated industries. He also provides counsel to several portfolio companies on a wide range of matters and builds and leads bespoke teams to deliver commercial solutions.

Andrew is a member of the Firm’s Cross-Border Steering Committee.

Charles (Chuck) Larsen provides clients sophisticated multijurisdictional counsel in intellectual property portfolio strategy, including patent prosecution, transactions, and disputes, with a particular emphasis in bio medical engineering and life sciences. He is licensed to practice before the US Patent and Trademark Office (USPTO), the European Patent Office (EPO), and the courts of England and Wales.

He has extensive experience in transactional IP matters, including transaction structuring and portfolio due diligence for investments and acquisitions, and negotiating collaboration license agreements, joint ventures, and other strategic commercial contracts involving key IP assets.

He also actively supports and counsels on transatlantic disputes, including US District Court cases, Patent Trial and Appeal Board (PTAB) proceedings, Reexaminations, EPO Oppositions, and litigation in Europe’s Unified Patent Court.

Chuck has advised on a wide range of technology in engineering and life sciences, including medical technology, pharmaceuticals, microfluidics, drug delivery, machine learning, signal processing, combustion, and energy. In the medical technology sector, his experience has involved a wide range of technologies, including medical diagnostics, intravascular devices, respiratory systems, orthopedic implants, cellular therapy, tissue engineering, neuromonitoring, spine technology, electrical stimulation, healthcare informatics, DNA sequencing, software driven devices, and biologic manufacturing.

Kyle Y. Faget advises a diverse client base – including life sciences companies, digital health platforms, virtual care providers, and academic medical centers – on regulatory, transactional, and compliance matters, with a focus on software as a medical device and artificial intelligence (AI) applications in healthcare. She has extensive experience in developing corporate compliance programs and regulatory strategies and provides guidance on US Food and Drug Administration (FDA) regulations for both established products and emerging technologies, including AI-enabled solutions.

Kyle counsels clients on the full spectrum of regulatory and compliance issues, including the Food, Drug, and Cosmetic Act; the False Claims Act; the Anti-Kickback Statute; and industry codes. She offers guidance on product marketing promotion compliance, assesses advertising materials and direct-to-consumer campaigns, and conducts sales-force training. She also oversees healthcare provider grants and charitable contributions and assesses research grants for healthcare professionals.

Kyle also advises on pharmacy supply chain contracting, laboratory and pharmacy relationships, and other healthcare service provider arrangements. She guides life sciences companies on market entry strategies and assists digital health innovators in navigating FDA requirements for emerging healthcare technologies. Her vast experience includes in-house positions at pre-commercial and commercial-stage pharmaceutical and medical device companies.

Kyle’s transactional experience encompasses pharmaceutical and medical device development and commercialization, including licensing agreements, manufacturing and distribution arrangements, collaboration agreements, clinical trial protocols, material transfer agreements, and healthcare professional engagement agreements.

Recognized for her deep experience in life sciences and healthcare law, Kyle is a prolific presenter and author. She frequently speaks at professional conferences and forums, developing topics in the context of her work and emerging technologies. She has published several articles in Health Care Law Today.